It has been reported that about 90% of the later stage pancreatic cancers have point mutations of KRAS, indicating that KRAS may be used as a diagnostic marker of PDAC (Campbell et al., 2007; De Oliveira et al., 2012; Zhang et al., 2014). This evidence concerns the gene KRAS and pancreatic neoplasm.